Fibrinogen — blood-clotting protein and acute-phase reactant

Structure and activation

Produced by hepatocytes in the liver, fibrinogen is built from three different polypeptide chains commonly called Aα, Bβ and γ. Two copies of this Aα–Bβ–γ unit assemble into the circulating molecule, which is therefore often described as a dimer or hexamer depending on the viewpoint. Short peptides on the Aα and Bβ chains — called fibrinopeptides — are removed enzymatically by thrombin during clot formation. Cleavage exposes polymerization sites that allow fibrin monomers to link, then factor XIIIa cross-links fibrin strands to create a stable network.

Biological roles and importance

Fibrinogen has several distinct roles: it is the substrate for fibrin clot formation, it bridges activated platelets via platelet integrin receptors to support aggregation, and it functions as an acute-phase reactant whose levels rise in inflammation. Because of these activities, fibrinogen influences bleeding, wound healing, and thrombotic risk, and it is implicated in cardiovascular disease, pregnancy complications, and inflammatory conditions.

Clinical measurement and disorders

Laboratory tests estimate fibrinogen concentration and functional activity using methods such as the Clauss assay and immunologic measurements. Abnormally low fibrinogen levels (hypofibrinogenemia or afibrinogenemia) lead to bleeding tendency, whereas qualitative defects (dysfibrinogenemia) can produce either bleeding or thrombosis depending on how polymerization and interaction with other factors are altered. Elevated fibrinogen is a nonspecific marker of inflammation and a contributor to hypercoagulability. Therapeutically, fibrinogen can be replaced with concentrates or cryoprecipitate in bleeding patients.

History, nomenclature and notable facts

The name "fibrinogen" denotes a precursor ("-ogen") of fibrin. It has been studied extensively as a central element of the coagulation cascade and as a biomarker linking inflammation and cardiovascular risk. Its dual role as a structural clotting protein and an acute-phase reactant makes it clinically useful for diagnosis and management across hematology, surgery and internal medicine.

Summary and further reading

• Key source of clot structure and platelet bridging (blood component).
• Synthesized in the liver and composed of Aα, Bβ and γ chains (protein structure).
• Activated by thrombin through removal of fibrinopeptides, then cross-linked by factor XIIIa.
• Measured clinically to evaluate bleeding, thrombotic risk, and inflammatory state.